載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.857
−US$0.0805 · -8.59%
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
收盤時
US$0.857
−US$0.0805 · -8.59%
盤後
US$0.88
+US$0.023 · +2.68%
10月13日 下午4:11 ET
盤中時間採用ET。市場資料可能有所延遲。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日內區間
目前US$0.857
52週區間
目前US$0.857
盤中時間採用ET。市場資料可能有所延遲。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日內區間
目前US$0.857
52週區間
目前US$0.857
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 85萬 USD | — | — | — |
| 銷貨成本 | 147.2萬 USD | — | — | — | — |
| 毛利 | −147.2萬 USD | 85萬 USD | — | — | — |
| 研究與開發 | 5596.9萬 USD | 4234.2萬 USD | 3812萬 USD | 2999.7萬 USD | 2033.7萬 USD |
| 銷售、一般及管理費用 | 1687萬 USD | 1513.3萬 USD | 1224.3萬 USD | 1165.8萬 USD | 1092.7萬 USD |
| 營業費用 | 7136.7萬 USD | 5747.5萬 USD | 5036.3萬 USD | 4165.5萬 USD | 8188.2萬 USD |
| 利息收入 | 635萬 USD | 730萬 USD | 790萬 USD | 236萬 USD | 2.9萬 USD |
| 利息支出 | — | — | — | 236萬 USD | 37萬 USD |
| 折舊和攤銷 | 147.2萬 USD | 175.3萬 USD | 189萬 USD | 190.4萬 USD | 162.4萬 USD |
| 營業利益 | −7283.9萬 USD | −5662.5萬 USD | −5036.3萬 USD | −4165.5萬 USD | −8188.2萬 USD |
| 淨利 | −6648.9萬 USD | −4937.5萬 USD | −4249.4萬 USD | −3922.5萬 USD | −8218.1萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.67
上漲空間 444.92%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1001.59萬0.00%2.3兆 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI470.12萬0.05%103.03億 USD0.35%US$146.8-3.04%
Vanguard Extended Market ETFVXF435.36萬0.00%954億 USD0.05%US$232.54-0.42%
iShares Russell 2000 ETFIWM322.72萬0.00%787.4億 USD0.19%US$276.71-0.43%
Vanguard Russell 2000 ETFVTWO180.34萬0.01%180億 USD0.06%US$111.77-0.45%
Fidelity Enhanced Small Cap ETFFESM153.36萬0.02%64.1億 USD0.28%US$45.15-0.20%
iShares Russell 2000 Value ETFIWN112.91萬0.01%137.49億 USD0.24%US$210.99-0.05%
Vanguard Health Care ETFVHT69.57萬0.00%220億 USD0.09%US$316.37-1.34%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Value ETFIWNVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
